Physician profile
Ryan Dorman
NPI 1144753765
$596.79
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $464 · 2020: $133.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $214.45 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $71.15 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $43.35 | 2019-2020 | |
| Abbvie INC. | $42.33 | 2019 | |
| Novartis Pharmaceuticals Corporation | $37.03 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $30.04 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $25.59 | 2019 | |
| Portola Pharmaceuticals, LLC | $21.69 | 2019 | |
| Edwards Lifesciences Corporation | $20.08 | 2019 | |
| Lantheus Medical Imaging, INC. | $19.52 | 2019 | |
| Mylan Specialty L.P. | $17.22 | 2019 | |
| Biosense Webster, INC. | $14.44 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $14.34 | 2020 | |
| Boston Scientific Corporation | $13.63 | 2019 | |
| Cumberland Pharmaceuticals, INC. | $11.93 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Dorman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.